Taylor Stanberry, 29, was introduced as the 2025 Florida Python Challenge winner on Aug. 13.

Her name is Taylor Stanberry and thanks to finding and eliminating 60 pythons in July, she's the 2025 winner of the Florida Python Challenge.

Is Recursion Pharma a buy because of Nvidia’s endorsement? Indeed, Nvidia’s bet on Recursion is notable, but despite the stake and collaboration, the name isn’t without its fair share of risks.

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.

Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpectedly well to treatment.

In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.27, denoting a +1.15% move from the preceding trading day.

With capital drying up and market tailwinds gone, the biotech industry — including Recursion — needs to make tactical decisions.

Recursion Pharmaceuticals plans to slash one-fifth of its workforce as it looks to streamline its operations. The clinical-stage biopharmaceutical company said Tuesday it will reduce its workforce ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.